Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Immunoproliferative Disorders 2Immune System Diseases 2Cytokine Release Syndrome 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Thymoma 1Thymic epithelial tumor 1Stomach Neoplasms 1Prostatic Neoplasms 1Neurotoxicity Syndromes 1Neoplasm, Residual 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Lymphoproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell 1Lymphoma 1Lymphohistiocytosis, Hemophagocytic 1Lymphatic Diseases 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1Hodgkin Disease 1Epstein-Barr Virus Infections 1Colorectal Neoplasms 1

Interventions

Cyclophosphamide 12fludarabine phosphate 7fludarabine 7venetoclax 6blinatumomab 6Cytarabine 5Lenalidomide 4Dexamethasone 4Blood Specimen Collection 4Azacitidine 4obinutuzumab 3Rituximab 3Radiotherapy 3Melphalan 3Immunotherapy, Adoptive 3pembrolizumab 2daratumumab 2Neoadjuvant Therapy 2Idarubicin 2Chemotherapy, Adjuvant 2Capecitabine 2trastuzumab deruxtecan 1tislelizumab 1tisagenlecleucel 1thymoglobulin 1tetrathiomolybdate 1talquetamab 1tagraxofusp 1sacituzumab govitecan 1sabatolimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm, Residual × AP 1903 reagent × 1 year × Clear all
NCT06358430 2026-05-20

Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

M.D. Anderson Cancer Center

Phase 1 Recruiting
42 enrolled
Gastrointestinal

Colorectal Neoplasms, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡